Gastroenterology Hub is intended for healthcare professionals working in the Republic of Ireland only.

Personalised care in Crohn’s disease (CD): Treat-to-target approaches

Mark Samaan MBBS BSc, Consultant Gastroenterologist at Guy’s and St Thomas’ NHS Foundation Trust

Watch Mark Samaan explain the concept of treat-to-target in CD, including how treatment goals are defined, assessed, and tailored to individual patients. 
Mark Samaan discusses the importance of aligning clinical and patient priorities and how STRIDE recommendations help guide treatment targets. He also reflects on the role of Entyvio® (vedolizumab)  in achieving long-term disease control in selected patients.

Adverse Events should be reported to the Pharmacovigilance Unit at the Health Products Regulatory Authority. Reporting forms and information can be found at: www.hpra.ie.  Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com.

C-APROM/IE/ENTY/0432 | August 2026

You are now leaving the Gastroenterology Hub

You are now leaving the Gastroenterology Hub

Personalised care in Crohn’s disease (CD): Treat-to-target approaches

Related content

Personalised care in Crohn’s disease (CD): Optimising treatment sequencing

Personalised care in Crohn’s disease (CD): Vedolizumab Clinical Decision Support Tool (VDZ-CDST), a treatment decision support tool

Personalised care in Crohn’s disease (CD): Vedolizumab Clinical Decision Support Tool (VDZ-CDST), a treatment  decision support tool